HR and cancer: A total of 53.5% of all of the women were diagnosed with stage 0 (ductal in situ carcinoma) or I, and the most frequent type of cancer was HR+/HER2− (76.4%), followed by HER2+ (15.4%) and triple negative (8.2%).